Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EWNYSE / NASDAQHealthcareLarge cap

$101.85-$2.03 (-2.0%)

Last close · Data as of Nov 20, 2026

Market cap
$50.4B
P/E
46.9x
EV / EBITDA
33.2x
Revenue
$6.1B
Net margin
17.7%
ROCE
13.8%

+21.1% over the last year

Edwards Lifesciences Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+15.4%
3M
+13.4%
6M
+22.8%
1Y
+21.1%
5Y
-13.0%

52-week range

Day change -$2.03 (-2.0%) from $104 to $102 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in EW, bought on each weekday since 2021.

News & filings

What Edwards Lifesciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 63.4 times interest costs.

Concerns (1)

  • The P/E of 46.9 is 36% above the peer median of 34.6.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.

Read moreShow less

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Sector
Healthcare
Shares outstanding
583.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$50.4B
P/E
46.9x
P/B
4.9x
EV / EBITDA
33.2x
EV / Sales
7.9x
P/S
8.3x
52-week high
$107.15
52-week low
$75.87

Profitability

Operating margin
27.0%
Net margin
17.7%
EBITDA margin
23.9%
ROE
10.4%
ROCE
13.8%
ROA
7.8%
Asset turnover
0.44

Growth

Revenue
$6.1B
Revenue growth, 1Y
11.5%
Revenue CAGR, 3Y
10.8%
Net profit growth, 1Y
-74.3%
Free cash flow
$1.3B

Solvency

Current ratio
3.72
Debt / Equity
0.07
Debt / Assets
0.05
CFO / Net profit
1.49
Cash / Market cap
5.8%

Where the revenue went

Of every $100 of FY2025 revenue, $18 was left as net income.

Edwards Lifesciences Corporation income statement flow, FY2025
Edwards Lifesciences Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.3B
RevenueGross profit$4.7B
Gross profitOperating expenses$3.1B
Gross profitOperating income$1.6B
Operating incomePretax income$1.3B
Operating incomeInterest and other expense$363.3M
Pretax incomeTax and other$199.4M
Pretax incomeNet income$1.1B

Revenue and net profit

Revenue grew 11.5% in FY2025; net profit is the dashed line.

Edwards Lifesciences Corporation revenue and net profit by fiscal year
Edwards Lifesciences Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$4.5B$1.5B
FY2023$5.0B$1.4B
FY2024$5.4B$4.2B
FY2025$6.1B$1.1B

Cash flows

FY2025: $1.6B from operations, $1.3B free after investment (dashed).

Edwards Lifesciences Corporation operating and free cash flow by fiscal year
Edwards Lifesciences Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.2B$953.4M
FY2023$895.8M$629.5M
FY2024$542.3M$259.9M
FY2025$1.6B$1.3B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$6.1B+11.5%1Y
EBITDA
$1.4B-15.9%1Y
Net profit
$1.1B-74.3%1Y
Cash from operations
$1.6B+194.2%1Y
Free cash flow
$1.3B+413.7%1Y
Revenue CAGR, 3Y
10.8%
Net profit CAGR, 3Y
-11.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$6.1B$1.4B$1.1B$1.3B—+11.5%-74.3%

Monthly returns

Month-by-month returns of EW across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$13.7B
Liabilities$3.4B
Equity$10.3B
Paid-in capital$2.8B
Retained earnings$14.2B
Treasury stock$7.1B
Minority interest$0.00

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; EW highlighted.

P/E against peers

EW trades at 46.9x earnings against a peer median of 34.6x (a 36% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Edwards Lifesciences CorporationEWthis companyP/E ↑ premium$50.4B46.9x4.9x10.4%33.2x
Cencora, Inc.COR$52.6B33.8x34.9x103.1%14.9x
Cardinal Health, Inc.CAH$47.2B30.3x-17.0x-56.1%16.7x
IDEXX Laboratories, Inc.IDXX$44.5B42.0x27.7x66.0%30.1x
Humana Inc.HUM$42.0B35.4x2.4x6.7%—
Becton, Dickinson and CompanyBDX$41.2B24.6x1.6x6.6%12.1x
Alnylam Pharmaceuticals, Inc.ALNY$40.5B129.2x51.4x39.8%61.6x
Agilent Technologies, Inc.A$39.1B30.0x5.8x19.3%22.1x
Waters CorporationWAT$37.0B57.5x14.4x25.1%36.7x
Peer median—34.6x10.1x22.2%22.1x

Year-to-date ROI

EW since 1 January, against earlier years.

Historical volatility

EW's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Edwards Lifesciences Corporation operating margin by fiscal year
Edwards Lifesciences Corporation operating margin by fiscal year
DateOperating margin
FY202234.5%
FY202329.7%
FY202427.2%
FY202527.0%
LineFY2025
Cost of revenueCost Of Revenue$1.3B
Gross profitGross Profit$4.7B
Operating expensesOperating Expense$3.1B
Research and developmentResearch And Development$1.1B
Other operating expensesOther Operating Expenses-$67.2M
Total expensesTotal Expenses$4.4B
Pretax incomePretax Income$1.3B

Learn while you research

Academy chapters picked for Edwards Lifesciences Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 46.9, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →